Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company’s future growth.
The WHO’s latest decision is based on advice from an independent panel of experts who evaluated data from 16 randomized controlled studies.
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
In what is sure to create widespread skepticism — or enthusiasm, a study published in Nature Aging found that use of erectile dysfunction medication Viagra was associated with a 69% lower incidence of Alzheimer’s disease.
Surrozen’s ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
In the staff documents, the FDA scientists expressed concerns over the Reata clinical data that was submitted.
Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.